Jeewoo Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6143748/publications.pdf

Version: 2024-02-01

194	4,671	101543	155660
papers	citations	36 h-index	55 g-index

207	207	207	4921
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-Î²-catenin signaling-mediated drug resistance and adverse effects. Theranostics, 2022, 12, 105-125.	10.0	23
2			

#	Article	IF	Citations
19	Discovery of novel heat shock protein (Hsp90) inhibitors based on luminespib with potent antitumor activity. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127165.	2.2	4
20	Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimerâ€™s Agents by Structure-Based Design. Journal of Medicinal Chemistry, 2019, 62, 8011-8027.	6.4	16
21	Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain. European Journal of Medicinal Chemistry, 2019, 182, 111634.	5.5	26
22	Differential effects of MEK inhibitors on rat neural stem cell differentiation: Repressive roles of MEK2 in neurogenesis and induction of astrocytogenesis by PD98059. Pharmacological Research, 2019, 149, 104466.	7.1	16
23	C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition. Cancer Letters, 2019, 447, 141-153.	7.2	34
24	Structure-activity relationship of leucyladenylate sulfamate analogues as leucyl-tRNA synthetase (LRS)-targeting inhibitors of Mammalian target of rapamycin complex 1 (mTORC1). Bioorganic and Medicinal Chemistry, 2019, 27, 1099-1109.	3.0	6
25	Differential Regulation of Gene Expression in Lung Cancer Cells by Diacyglycerol-Lactones and a Phorbol Ester Via Selective Activation of Protein Kinase C Isozymes. Scientific Reports, 2019, 9, 6041.	3.3	22
26	Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents. Bioorganic and Medicinal Chemistry, 2019, 27, 1370-1381.	3.0	16
27	Functional Group-Dependent Induction of Astrocytogenesis and Neurogenesis by Flavone Derivatives. Biomolecules, 2019, 9, 812.	4.0	5
28	In vitroandin silicodetermination of glutaminyl cyclase inhibitors. RSC Advances, 2019, 9, 29619-29627.	3.6	14
29	Combination of a Rapidly Penetrating Agonist and a Slowly Penetrating Antagonist Affords Agonist Action of Limited Duration at the Cellular Level. Biomolecules and Therapeutics, 2019, 27, 435-441.	2.4	1
30	Structure-activity relationship investigation of Phe-Arg mimetic region of human glutaminyl cyclase inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 3133-3144.	3.0	16
31	Curcumin interacts directly with the Cysteine 259 residue of STAT3 and induces apoptosis in H-Ras transformed human mammary epithelial cells. Scientific Reports, 2018, 8, 6409.	3.3	64
32	Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimerâ€™s agents: Structure-activity relationship study of Arg-mimetic region. Bioorganic and Medicinal Chemistry, 2018, 26, 1035-1049.	3.0	19
33	Synthesis and biological evaluation of 3-(2-aminoethyl) uracil derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists. European Journal of Medicinal Chemistry, 2018, 145, 413-424.	5.5	5
34	Discovery of an Orally Bioavailable Benzofuran Analogue That Serves as a Î²-Amyloid Aggregation Inhibitor for the Potential Treatment of Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2018, 61, 396-402.	6.4	30
35	Comparative Effects of Curcumin and Tetrahydrocurcumin on Dextran Sulfate Sodium-induced Colitis and Inflammatory Signaling in Mice. Journal of Cancer Prevention, 2018, 23, 18-24.	2.0	32
36	Novel Hypoxia-Inducible Factor 1Î± (HIF-1Î±) Inhibitors for Angiogenesis-Related Ocular Diseases: Discovery of a Novel Scaffold via Ring-Truncation Strategy. Journal of Medicinal Chemistry, 2018, 61, 9266-9286.	6.4	30

#	Article	IF	Citations
37	Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer. Scientific Reports, 2018, 8, 13924.	3.3	23
38	Discovery of 2-(3,5-difluoro-4-methylsulfonaminophenyl)propanamides as potent TRPV1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2539-2542.	2.2	3
39	Curcumin suppresses oncogenicity of human colon cancer cells by covalently modifying the cysteine 67 residue of SIRT1. Cancer Letters, 2018, 431, 219-229.	7.2	60
40	4-Aminophenyl acetamides and propanamides as potent transient receptor potential vanilloid 1 (TRPV1) ligands. Bioorganic and Medicinal Chemistry, 2018, 26, 4509-4517.	3.0	5
41	Discovery of novel leucyladenylate sulfamate surrogates as leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 4073-4079.	3.0	11
42	Î±-Arylidene Diacylglycerol-Lactones (DAG-Lactones) as Selective Ras Guanine-Releasing Protein 3 (RasGRP3) Ligands. Journal of Medicinal Chemistry, 2018, 61, 6261-6276.	6.4	4
43	Characterization of AJH-836, a diacylglycerol-lactone with selectivity for novel PKC isozymes. Journal of Biological Chemistry, 2018, 293, 8330-8341.	3.4	22
44	Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimerâ€™s Agents Based on Rational Design. Journal of Medicinal Chemistry, 2017, 60, 2573-2590.	6.4	33
45	Discovery of simplified leucyladenylate sulfamates as novel leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 4145-4152.	3.0	16
46	t-Butyl pyridine and phenyl C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists. Bioorganic and Medicinal Chemistry, 2017, 25, 2451-2462.	3.0	8
47	Novel Radiolabeled Vanilloid with Enhanced Specificity for Human Transient Receptor Potential Vanilloid 1 (TRPV1). Journal of Medicinal Chemistry, 2017, 60, 8246-8252.	6.4	6
48	Pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4383-4388.	2.2	16
49	Discovery of (S)-4-isobutyloxazolidin-2-one as a novel leucyl-tRNA synthetase (LRS)-targeted mTORC1 inhibitor. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3038-3041.	2.2	16
50	Discovery of an Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist. Journal of Medicinal Chemistry, 2016, 59, 9150-9172.	6.4	15
51	Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 6082-6093.	3.0	24
52	Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-Targeted Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 10322-10328.	6.4	15
53	Discovery of N-(3-fluoro-4-methylsulfonamidomethylphenyl)urea as a potent TRPV1 antagonistic template. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3603-3607.	2.2	11
54	2-Sulfonamidopyridine C-region analogs of 2-(3-fluoro-4-methylsulfonamidophenyl)propanamides as potent TRPV1 antagonists. Bioorganic and Medicinal Chemistry, 2016, 24, 1231-1240.	3.0	10

#	Article	IF	Citations
55	Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity. Cancer Research, 2016, 76, 686-699.	0.9	41
56	Discovery of a Small Molecule that Enhances Astrocytogenesis by Activation of STAT3, SMAD1/5/8, and ERK1/2 via Induction of Cytokines in Neural Stem Cells. ACS Chemical Neuroscience, 2016, 7, 90-99.	3.5	16
57	6,6-Fused heterocyclic ureas as highly potent TRPV1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 803-806.	2.2	5
58	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 â€“ 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 291-318.	5.0	65
59	Pyridine C-region analogs of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists. European Journal of Medicinal Chemistry, 2015, 93, 101-108.	5.5	13
60	Fine tuning of 4,6-bisphenyl-2-(3-alkoxyanilino)pyrimidine focusing on the activity-sensitive aminoalkoxy moiety for a therapeutically useful inhibitor of receptor for advanced glycation end products (RAGE). Bioorganic and Medicinal Chemistry, 2015, 23, 579-587.	3.0	13
61	Î±-Substituted 2-(3-fluoro-4-methylsulfonamidophenyl)acetamides as potent TRPV1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2326-2330.	2.2	11
62	Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90. Molecular Pharmacology, 2015, 88, 245-255.	2.3	38
63	6-Phenoxy-2-phenylbenzoxazoles, novel inhibitors of receptor for advanced glycation end products (RAGE). Bioorganic and Medicinal Chemistry, 2015, 23, 4919-4935.	3.0	11
64	Beyond the affinity for protein kinase C: exploring 2-phenyl-3-hydroxypropyl pivalate analogues as C1 domain-targeting ligands. MedChemComm, 2015, 6, 547-554.	3.4	6
65	Structure activity relationships of benzyl C-region analogs of 2-(3-fluoro-4-methylsulfonamidophenyl)propanamides as potent TRPV1 antagonists. Bioorganic and Medicinal Chemistry, 2015, 23, 6844-6854.	3.0	8
66	Ring-truncated deguelin derivatives as potent Hypoxia Inducible Factor-1Î± (HIF-1Î±) inhibitors. European Journal of Medicinal Chemistry, 2015, 104, 157-164.	5.5	24
67	Design and synthesis of protein kinase C epsilon selective diacylglycerol lactones (DAG-lactones). European Journal of Medicinal Chemistry, 2015, 90, 332-341.	5.5	10
68	An Aminopropyl Carbazole Derivative Induces Neurogenesis by Increasing Final Cell Division in Neural Stem Cells. Biomolecules and Therapeutics, 2015, 23, 313-319.	2.4	11
69	Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB Journal, 2014, 28, 3197-3204.	0.5	164
70	Migration of neutrophils targeting amyloid plaques in Alzheimer's disease mouse model. Neurobiology of Aging, 2014, 35, 1286-1292.	3.1	146
71	Pyrazole-5-carboxamides, novel inhibitors of receptor for advanced glycation end products (RAGE). European Journal of Medicinal Chemistry, 2014, 79, 128-142.	5.5	60
72	Asymmetric synthesis and receptor activity of chiral simplified resiniferatoxin (sRTX) analogues as transient receptor potential vanilloid 1 (TRPV1) ligands. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 382-385.	2.2	11

#	Article	IF	Citations
73	Hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retina is suppressed by HIF-1Î± destabilization by SH-1242 and SH-1280, novel hsp90 inhibitors. Journal of Molecular Medicine, 2014, 92, 1083-1092.	3.9	36
74	2-Alkyl/alkenyl substituted pyridine C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as highly potent TRPV1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4039-4043.	2.2	15
75	Î±-Methylated simplified resiniferatoxin (sRTX) thiourea analogues as potent and stereospecific TRPV1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2685-2688.	2.2	5
76	2-Aryl substituted pyridine C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as highly potent TRPV1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4044-4047.	2.2	16
77	Inhibition of Glutaminyl Cyclase Ameliorates Amyloid Pathology in an Animal Model of Alzheimer's Disease via the Modulation of Î³-Secretase Activity. Journal of Alzheimer's Disease, 2014, 43, 797-807.	2.6	12
78	TRPV1 antagonist with high analgesic efficacy: 2-Thio pyridine C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides. Bioorganic and Medicinal Chemistry, 2013, 21, 6657-6664.	3.0	20
79	Aminopropyl carbazole analogues as potent enhancers of neurogenesis. Bioorganic and Medicinal Chemistry, 2013, 21, 7165-7174.	3.0	30
80	A two-photon fluorescent probe for amyloid-Î² plaques in living mice. Chemical Communications, 2013, 49, 1303.	4.1	54
81	The carbonate analogues of 5â€²-halogenated resiniferatoxin as TRPV1 ligands. European Journal of Medicinal Chemistry, 2013, 68, 233-243.	5.5	6
82	2-(3-Fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists: Structure activity relationships of the 2-oxy pyridine C-region. European Journal of Medicinal Chemistry, 2013, 64, 589-602.	5.5	21
83	Structureâ€“activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template. Bioorganic and Medicinal Chemistry, 2013, 21, 3821-3830.	3.0	33
84	Contributions of TRPV1, endovanilloids, and endoplasmic reticulum stress in lung cell death in vitro and lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2012, 302, L111-L119.	2.9	39
85	Transient Receptor Potential Vanilloid-1 (TRPV1) Is a Mediator of Lung Toxicity for Coal Fly Ash Particulate Material. Molecular Pharmacology, 2012, 81, 411-419.	2.3	58
86	The SAR analysis of TRPV1 agonists with the Î±-methylated B-region. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5227-5231.	2.2	5
87	2-(3-Fluoro-4-methylsulfonylaminophenyl)propanamides as Potent Transient Receptor Potential Vanilloid 1 (TRPV1) Antagonists: Structureâ€“Activity Relationships of 2-Amino Derivatives in the N-(6-Trifluoromethylpyridin-3-ylmethyl) C-Region. Journal of Medicinal Chemistry, 2012, 55, 8392-8408.	6.4	36
88	Intracellular Amyloid-Î² Accumulation in Calcium-Binding Protein-Deficient Neurons Leads to Amyloid-Î² Plaque Formation in Animal Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 29, 615-628.	2.6	53
89	Ligand-Based Design, Synthesis, and Biological Evaluation of 2-Aminopyrimidines, a Novel Series of Receptor for Advanced Glycation End Products (RAGE) Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 9120-9135.	6.4	52
90	N-4-t-Butylbenzyl 2-(4-methylsulfonylaminophenyl) propanamide TRPV1 antagonists: Structureâ€“activity relationships in the A-region. Bioorganic and Medicinal Chemistry, 2012, 20, 215-224.	3.0	12

#	Article	IF	Citations
91	2-(4-Methylsulfonylaminophenyl) propanamide TRPV1 antagonists: Structureâ€“activity relationships in the B and C-regions. Bioorganic and Medicinal Chemistry, 2012, 20, 1310-1318.	3.0	4
92	Structureâ€“activity relationships and molecular modeling of the N-(3-pivaloyloxy-2-benzylpropyl)-Nâ€²-[4-(methylsulfonylamino)benzyl] thiourea template for TRPV1 antagonism. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3656-3660.	2.2	6
93	TRPV1 Activation is Not An All-Or-None Event: TRPV1 Partial Agonism/Antagonism and Its Regulatory Modulation. Current Topics in Medicinal Chemistry, 2011, 11, 2151-2158.	2.1	22
94	Structural insights into transient receptor potential vanilloid type 1 (TRPV1) from homology modeling, flexible docking, and mutational studies. Journal of Computer-Aided Molecular Design, 2011, 25, 317-327.	2.9	64
95	Physiologically based pharmacokinetic modeling of SNU-0039, an anti-Alzheimerâ€™s agent, in rats. Journal of Pharmacokinetics and Pharmacodynamics, 2011, 38, 637-651.	1.8	5
96	Receptor activity and conformational analysis of 5â€²-halogenated resiniferatoxin analogs as TRPV1 ligands. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 299-302.	2.2	5
97	Structure-Activity Relationship of Capsaicin Analogs and Transient Receptor Potential Vanilloid 1-Mediated Human Lung Epithelial Cell Toxicity. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 400-410.	2.5	40
98	Polar 3-alkylidene-5-pivaloyloxymethyl-5â€²-hydroxymethyl-Î³-lactones as protein kinase C ligands and antitumor agents. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1008-1012.	2.2	6
99	Halogenation of 4-hydroxy/amino-3-methoxyphenyl acetamide TRPV1 agonists showed enhanced antagonism to capsaicin. Bioorganic and Medicinal Chemistry, 2010, 18, 8092-8105.	3.0	5
100	2-[2-Substituted-3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-4-ones as Staphylococcus aureus methionyl-tRNA synthetase inhibitors. European Journal of Medicinal Chemistry, 2009, 44, 239-250.	5.5	25
101	Conformationally constrained analogues of Nâ€²-(4-tert-butylbenzyl)-N-(4-methylsulfonylaminobenzyl)thiourea as TRPV1 antagonists. European Journal of Medicinal Chemistry, 2009, 44, 322-331.	5.5	4
102	Non-vanillyl resiniferatoxin analogues as potent and metabolically stable transient receptor potential vanilloid 1 agonists. Bioorganic and Medicinal Chemistry, 2009, 17, 690-698.	3.0	9
103	Differential modulation of agonist and antagonist structure activity relations for rat TRPV1 by cyclosporin A and other protein phosphatase inhibitors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 377, 149-157.	3.0	16
104	Stereospecific High-affinity TRPV1 Antagonists: Chiral N-(2-Benzyl-3-pivaloyloxypropyl) 2-[4-(methylsulfonylamino)phenyl]propionamide Analogues. Journal of Medicinal Chemistry, 2008, 51, 57-67.	6.4	30
105	Dorsal Root Ganglion Neurons Innervating Skeletal Muscle Respond to Physiological Combinations of Protons, ATP, and Lactate Mediated by ASIC, P2X, and TRPV1. Journal of Neurophysiology, 2008, 100, 1184-1201.	1.8	246
106	Conformationally Constrained Analogues of Diacylglycerol. 29. Cells Sort Diacylglycerol-Lactone Chemical Zip Codes to Produce Diverse and Selective Biological Activities. Journal of Medicinal Chemistry, 2008, 51, 5198-5220.	6.4	40
107	Î±-Substituted N-(4-tert-butylbenzyl)-Nâ€²-[4-(methylsulfonylamino)benzyl]thiourea analogues as potent and stereospecific TRPV1 antagonists. Bioorganic and Medicinal Chemistry, 2007, 15, 6043-6053.	3.0	25
108	Halogenation of 4-hydroxy-3-methoxybenzyl thiourea TRPV1 agonists showed enhanced antagonism to capsaicin. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 214-219.	2.2	9

#	Article	IF	Citations
109	Branched Diacylglycerol-Lactones as Potent Protein Kinase C Ligands and Î±-Secretase Activators. Journal of Medicinal Chemistry, 2006, 49, 2028-2036.	6.4	11
110	Pharmacophore-based virtual screening: The discovery of novel methionyl-tRNA synthetase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4898-4907.	2.2	21
111	2-Benzyl and 2-phenyl-3-hydroxypropyl pivalates as protein kinase C ligands. Bioorganic and Medicinal Chemistry, 2006, 14, 2022-2031.	3.0	15
112	Design and synthesis of quinolinones as methionyl-tRNA synthetase inhibitors. Bioorganic and Medicinal Chemistry, 2006, 14, 7154-7159.	3.0	22
113	Kinetics of Penetration Influence the Apparent Potency of Vanilloids on TRPV1. Molecular Pharmacology, 2006, 69, 1166-1173.	2.3	34
114	Deoxyribosyl analogues of methionyl and isoleucyl sulfamate adenylates as inhibitors of methionyl-tRNA and isoleucyl-tRNA synthetases. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3389-3393.	2.2	22
115	Analysis of structureâ€“activity relationships for the â€˜B-regionâ€™ of N-(4-t-butylbenzyl)-Nâ€²-[4-(methylsulfonylamino)benzyl]-thiourea analogues as TRPV1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4143-4150.	2.2	14
116	Calcium-dependent and independent mechanisms of capsaicin receptor (TRPV1)-mediated cytokine production and cell death in human bronchial epithelial cells. Journal of Biochemical and Molecular Toxicology, 2005, 19, 266-275.	3.0	74
117	Analysis of structureâ€“activity relationships for the â€˜A-regionâ€™ of N-(4-t-butylbenzyl)-Nâ€²-[4-(methylsulfonylamino)benzyl]thiourea analogues as TRPV1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4136-4142.	2.2	18
118	Different vanilloid agonists cause different patterns of calcium response in CHO cells heterologously expressing rat TRPV1. Life Sciences, 2005, 76, 2921-2932.	4.3	44
119	Novel Potent Antagonists of Transient Receptor Potential Channel, Vanilloid Subfamily Member 1:Â Structureâ^'Activity Relationship of 1,3-Diarylalkyl Thioureas Possessing New Vanilloid Equivalents. Journal of Medicinal Chemistry, 2005, 48, 5823-5836.	6.4	40
120	Chain-branched 1,3-dibenzylthioureas as vanilloid receptor 1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 1751-1755.	2.2	10
121	Analysis of structureâ€“activity relationships for the â€˜B-regionâ€™ of N -(3-acyloxy-2-benzylpropyl)- N â€² -[4-(methylsulfonylamino)benzyl]thiourea analogues as vanilloid receptor antagonists: discovery of an N -hydroxythiourea analogue with potent analgesic activity. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2291-2297.	2.2	13
122	N -[4-(Methylsulfonylamino)benzyl]thiourea analogues as vanilloid receptor antagonists: analysis of structureâ€“activity relationships for the â€˜C-Regionâ€™. Bioorganic and Medicinal Chemistry, 2004, 12, 371-385.	3.0	33
123	Structureâ€“activity relationships of simplified resiniferatoxin analogues with potent VR1 agonism elucidates an active conformation of RTX for VR1 binding. Bioorganic and Medicinal Chemistry, 2004, 12, 1055-1069.	3.0	9
124	3D-QSAR analysis of conformationally constrained diacylglycerol (DAG) analogues as potent protein kinase C (PK-C) ligands. Bioorganic and Medicinal Chemistry, 2004, 12, 2639-2644.	3.0	3
125	Analysis of structureâ€“activity relationships with the N-(3-acyloxy-2-benzylpropyl)-Nâ€²-[4-(methylsulfonylamino)benzyl]thiourea template for vanilloid receptor 1 antagonism. Bioorganic and Medicinal Chemistry, 2004, 12, 3411-3420.	3.0	14
126	Synthesis and evaluation of fluorine-substituted 1H-pyrrolo[2,3-b]pyridine derivatives for dopamine D4 receptor imaging. Bioorganic and Medicinal Chemistry, 2004, 12, 5505-5513.	3.0	26

#	Article	IF	Citations
127	Conformationally constrained diacylglycerol (DAG) analogs: 4-C-hydroxyethyl-5-O-acyl-2,3-dideoxy-D-glyceropentono-1,4-lactone analogs as protein kinase C (PKC) ligands. European Journal of Medicinal Chemistry, 2004, 39, 69-77.	5.5	4
128	N-4-Substituted-benzyl-Nâ€²-tert-butylbenzyl thioureas as vanilloid receptor ligands: investigation on the role of methanesulfonamido group in antagonistic activity. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 787-791.	2.2	29
129	Synthesis of 7â€²-[123 I]iodo- d -luciferin for in vivo studies of firefly luciferase gene expression. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 1161-1163.	2.2	9
130	Macrocyclic Diacylglycerol-bis-lactones as Conformationally Constrained Analogues of Diacylglycerol-lactones. Interactions with Protein Kinase C. Journal of Medicinal Chemistry, 2004, 47, 4000-4007.	6.4	23
131	Conformationally Constrained Analogues of Diacylglycerol. 24. Asymmetric Synthesis of a Chiral (R)-DAG-Lactone Template as a Versatile Precursor for Highly Functionalized DAG-Lactones. Organic Letters, 2004, 6, 2413-2416.	4.6	31
132	Novel non-vanilloid VR1 antagonist of high analgesic effects and its structural requirement for VR1 antagonistic effects. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 4389-4393.	2.2	36
133	3-D-QSAR study and molecular docking of methionyl-tRNA synthetase inhibitors. Bioorganic and Medicinal Chemistry, 2003, 11, 5325-5331.	3.0	11
134	N-Alkoxysulfamide, N-hydroxysulfamide, and sulfamate analogues of methionyl and isoleucyl adenylates as inhibitors of methionyl-tRNA and isoleucyl-tRNA synthetases. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1087-1092.	2.2	38
135	Conformationally constrained analogues of diacylglycerol (DAG). Effect on protein kinase C (PK-C) binding by the isosteric replacement of sn-1 and sn-2 esters in DAG-lactones. Bioorganic and Medicinal Chemistry, 2003, 11, 2529-2539.	3.0	19
136	Synthesis of 2-substituted-pyrrolidinethiourea derivatives and their antagonist effect on vanilloid receptor. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 197-200.	2.2	16
137	Synthesis of N,Nâ€²,Nâ€³-trisubstituted thiourea derivatives and their antagonist effect on the vanilloid receptor. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 601-604.	2.2	21
138	N-(3-Acyloxy-2-benzylpropyl)-Nâ€˜-[4-(methylsulfonylamino)benzyl]thiourea Analogues:Â Novel Potent and High Affinity Antagonists and Partial Antagonists of the Vanilloid Receptor. Journal of Medicinal Chemistry, 2003, 46, 3116-3126.	6.4	110
139	Conformationally Constrained Analogues of Diacylglycerol. 19. Synthesis and Protein Kinase C Binding Affinity of Diacylglycerol Lactones Bearing an N-Hydroxylamide Side Chain. Journal of Medicinal Chemistry, 2003, 46, 2790-2793.	6.4	18
140	Lovastatin enhances AÎ² production and senile plaque deposition in female Tg2576 mice. Neurobiology of Aging, 2003, 24, 637-643.	3.1	131
141	High-Affinity Partial Agonists of the Vanilloid Receptor. Molecular Pharmacology, 2003, 64, 325-333.	2.3	38
142	High Affinity Antagonists of the Vanilloid Receptor. Molecular Pharmacology, 2002, 62, 947-956.	2.3	97
143	Diacylglycerol (DAG)-lactones, a New Class of Protein Kinase C (PKC) Agonists, Induce Apoptosis in LNCaP Prostate Cancer Cells by Selective Activation of PKCÎ±. Journal of Biological Chemistry, 2002, 277, 645-655.	3.4	88
144	Inhibition of Mouse Skin Tumor Promotion by Anti-Inflammatory Diarylheptanoids Derived From Alpinia oxyphylla Miquel (Zingiberaceae). Oncology Research, 2002, 13, 37-45.	1.5	64

#	Article	IF	Citations
145	Phenolic Modification as an Approach to Improve the Pharmacology of the 3-Acyloxy-2-benzylpropyl Homovanillic Amides and Thioureas, a Promising Class of Vanilloid Receptor Agonists and Analgesics. Bioorganic and Medicinal Chemistry, 2002, 10, 1171-1179.	3.0	14
146	Conformationally constrained analogues of diacylglycerol (DAG). Part 19: Asymmetric syntheses of (3R)- and (3S)-3-hydroxy-4,4-disubstituted heptono-1,4-lactones as protein kinase C (PK-C) ligands with increased hydrophilicity. Tetrahedron, 2002, 58, 5335-5345.	1.9	12
147	A simple and efficient in vitro method for metabolism studies of radiotracers. Nuclear Medicine and Biology, 2001, 28, 391-395.	0.6	16
148	Conformationally Constrained Analogues of Diacylglycerol. 18. The Incorporation of a Hydroxamate Moiety into Diacylglycerol-Lactones Reduces Lipophilicity and Helps Discriminate between sn-1 and sn-2 Binding Modes to Protein Kinase C (PK-C). Implications for Isozyme Specificity. Journal of Medicinal Chemistry, 2001, 44, 4309-4312.	6.4	16
149	A comparative study of quantitative structure activity relationship methods based on antitumor diarylsulfonylureas. European Journal of Medicinal Chemistry, 2001, 36, 829-836.	5.5	14
150	Ester and hydroxamate analogues of methionyl and isoleucyl adenylates as inhibitors of methionyl-tRNA and isoleucyl-tRNA synthetases. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 961-964.	2.2	30
151	Vanilloid and isovanilloid analogues as inhibitors of methionyl-tRNA and isoleucyl-tRNA synthetases. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 965-968.	2.2	23
152	N-(3-acyloxy-2-benzylpropyl)-Nâ€²-(4-hydroxy-3-methoxybenzyl)thiourea derivatives as potent vanilloid receptor agonists and analgesics. Bioorganic and Medicinal Chemistry, 2001, 9, 19-32.	3.0	49
153	N-(3-Acyloxy-2-Benzylpropyl)-Nâ€²-Dihydroxytetrahydrobenzazepine and Tetrahydroisoquinoline Thiourea Analogues as Vanilloid Receptor Ligands. Bioorganic and Medicinal Chemistry, 2001, 9, 1713-1720.	3.0	22
154	5-Acyloxy-5-hydroxymethyltetrahydro-2-furancarboxylate as a novel template for protein kinase C (PKC) binding. Il Farmaco, 2001, 56, 203-210.	0.9	3
155	Synthesis and biological evaluation of 1-(4-[18f]fluorobenzyl)-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine for in vivo studies of acetylcholinesterase. Nuclear Medicine and Biology, 2000, 27, 741-744.	0.6	15
156	Conformationally Constrained Analogues of Diacylglycerol (DAG). 16.1How Much Structural Complexity Is Necessary for Recognition and High Binding Affinity to Protein Kinase C?. Journal of Medicinal Chemistry, 2000, 43, 921-944.	6.4	75
157	Methionyl adenylate analogues as inhibitors of methionyl-tRNA synthetase. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 1365-1370.	2.2	42
158	3-Acyloxy-2-phenalkylpropyl amides and esters of homovanillic acid as novel vanilloid receptor agonists. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2909-2914.	2.2	17
159	The Transition from a Pharmacophore-Guided Approach to a Receptor-Guided Approach in the Design of Potent Protein Kinase C Ligands. , 1999, 82, 251-261.		40
160	Anti-tumor promoting potential of naturally occurring diarylheptanoids structurally related to curcumin. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1999, 428, 49-57.	1.0	49
161	Protein Kinase C Ligands Based on Tetrahydrofuran Templates Containing a New Set of Phorbol Ester Pharmacophores. Journal of Medicinal Chemistry, 1999, 42, 4129-4139.	6.4	11
162	A Facile and Practical Synthesis of Capsazepine, a Vanilloid Receptor Antagonist. Synthetic Communications, 1999, 29, 4127-4140.	2.1	6

#	Article	IF	Citations
163	Conformationally constrained analogues of diacylglycerol having a perhydrofuro[3,4-c]furan-1,4-dione bis-Î³-butyrolactone skeleton. Archives of Pharmacal Research, 1998, 21, 164-167.	6.3	1
164	Synthesis and biological activity of 5-hydroxy-4-quinolones and 5-methoxy-4-quinolones as truncated acridones. Archives of Pharmacal Research, 1998, 21, 445-451.	6.3	1
165	Design and synthesis of bioisosteres of ultrapotent protein kinase C (PKC) ligand, 5-Acetoxymethyl-5-hydroxymethyl-3-alkylidene tetrahydro-2-furanone. Archives of Pharmacal Research, 1998, 21, 452-457.	6.3	10
166	Conformationally constrained analogues of diacylglycerol (DAG). 14.1 Dissection of the roles of the sn-1 and sn-2 carbonyls in DAG mimetics by isopharma cophore replacement. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 1757-1762.	2.2	16
167	Methionine analogues as inhibitors of methionyl-tRNA synthetase. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 3511-3514.	2.2	15
168	Synthesis and biological activities of truncated acridone: Structure-activity relationship studies of cytotoxic 5-hydroxy-4-quinolone. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 789-792.	2.2	11
169	Syntheses and antiviral activities of 1,3-dioxolanyl-, 1,3-oxathiolanyl- and 1,3-dithiolanylnucleosides with 2-hydroxymethyl substituents. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1475-1480.	2.2	11
170	Conformationally Constrained Analogues of Diacylglycerol. 10. Ultrapotent Protein Kinase C Ligands Based on a Racemic 5-Disubstituted Tetrahydro-2-furanone Template1. Journal of Medicinal Chemistry, 1996, 39, 19-28.	6.4	44
171	Conformationally Constrained Analogues of Diacylglycerol. 13.1Protein Kinase C Ligands Based on Templates Derived from 2,3-Dideoxy-l-erythro(threo)-hexono-1,4-lactone and 2-Deoxyapiolactone. Journal of Medicinal Chemistry, 1996, 39, 4912-4919.	6.4	14
172	Conformationally Constrained Analogues of Diacylglycerol. 12.1Ultrapotent Protein Kinase C Ligands Based on a Chiral 4,4-Disubstituted Heptono-1,4-lactone Template. Journal of Medicinal Chemistry, 1996, 39, 36-45.	6.4	35
173	Distinct structure-activity relations for stimulation of 45Ca uptake and for high affinity binding in cultured rat dorsal root ganglion neurons and dorsal root ganglion membranes. Molecular Brain Research, 1996, 35, 173-182.	2.3	63
174	Conformationally Constrained Analogues of Diacylglycerol. 11.1Ultrapotent Protein Kinase C Ligands Based on a Chiral 5-Disubstituted Tetrahydro-2-furanone Template. Journal of Medicinal Chemistry, 1996, 39, 29-35.	6.4	37
175	Synthesis and antiviral activity of fluoro sugar nucleosides 2: Synthesis and biological evaluations of 2â€², 3â€²-dideoxy-2â€²-fluoro-3â€²-C-hydroxymethyl-Î²-D-arabinofuranosyl nucleosides. Archives of Pharmacal Research, 1996, 19, 243-245.	6.3	1
176	Synthesis of bis-Î³-butyrolactones containing conformationally constrained (S)- and (R) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222 Td ()	3.0	4
177	Synthesis of a Rigid Diacylglycerol Analogue Having a Bis-Î³-butyrolactone Skeleton Separated by a Cyclopentane Ring. Chemistry Letters, 1995, 24, 299-300.	1.3	2
178	Design and synthesis of heterocyclic analogues of mycophenolic acid as potential chemotherapeutic agents. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 861-866.	2.2	3
179	Thiourea analogues of resiniferatoxin as ligands for the vanilloid receptor. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 1331-1334.	2.2	8
180	Resiniferatoxinâ€Amide and Analogues as Ligands for Protein Kinase C and Vanilloid Receptors and Determination of Their Biological Activities as Vanilloids. Journal of Neurochemistry, 1995, 65, 301-308.	3.9	24

#	Article	IF	Citations
181	Synthesis of two Rigid Diacylglycerol Analogues Having a 1,7-Dioxasjuro[4.4]nonane Bis-Î³-butyrolactone Skeleton.4.1. Synlett, 1994, 1994, 206-208.	1.8	9
182	Conformationally constrained analogues of diacylglycerol. 6. Changes in PK-C binding affinity for 3-O-acyl-2-deoxy-L-ribonolactones bearing different acyl chains.. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 355-360.	2.2	11
183	Conformationally constrained analogues of DAG.7. Interaction of a medium-size Îµ-lactone with protein kinase C (PK-C)_. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 543-548.	2.2	5
184	Conformationally constrained analogues of dag .8. Changes in PK-C binding affinity produced by isosteric groups of the 3-O-acyl function in 2-deoxy-L-ribonolactones. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 1369-1374.	2.2	5
185	Conformationally constrained analogues of diacylglycerol. 9.1 the effect of side-chain orientation on the protein kinase C (PK-C) binding affinity of Ïƒ-lactones. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 2405-2410.	2.2	6
186	Protein Kinase C. Modeling of the Binding Site and Prediction of Binding Constants. [Erratum to document cited in CA121:29778]. Journal of Medicinal Chemistry, 1994, 37, 4422-4422.	6.4	0
187	Protein Kinase C. Modeling of the Binding Site and Prediction of Binding Constants. Journal of Medicinal Chemistry, 1994, 37, 1326-1338.	6.4	40
188	Synthesis of two rigid diacylglycerol analogues having a perhydro furo[34-b]furan bis-Î³-butyrolactone skeleton. 2.. Tetrahedron Letters, 1993, 34, 4313-4316.	1.4	6
189	Conformationally constrained analogues of diacylglycerol (DAG). 3. Interaction of Î±-alkyl-Î³-lactones with protein kinase C (PK-C). Bioorganic and Medicinal Chemistry Letters, 1993, 3, 1101-1106.	2.2	10
190	Conformationally constrained analogues of diacylglycerol (DAG). 4. Interaction of Î±-alkylidene-Î³-lactones with protein kinase C (PK-C). Bioorganic and Medicinal Chemistry Letters, 1993, 3, 1107-1110.	2.2	7
191	Conformationally constrained analogues of diacylglycerol (DAG)-II. Differential interaction of Î´-lactones and Î³-lactones with protein kinase C (PK-C). Bioorganic and Medicinal Chemistry, 1993, 1, 119-123.	3.0	8
192	Synthesis of two rigid diacylglycerol analogues having a perhydro furo[3,2-b]furan bis-Î³-butyrolactone skeleton. 3.. Tetrahedron Letters, 1993, 34, 4317-4320.	1.4	6
193	A Facile Synthesis of an (E)-4-Methyl-4-Hexenoic Acid Substituted Pyridine Analogue of Mycophenolic Acid. Synthetic Communications, 1992, 22, 369-376.	2.1	12
194	Synthesis of two rigid diacylglycerol analogues having a bis-butyrolactone skeleton. Tetrahedron Letters, 1992, 33, 1539-1542.	1.4	13